Technology | May 29, 2013

Hologic Receives FDA Approval for Low-Dose 3-D Mammography

Breast tomosynthesis solution may offer more accurate method for breast cancer screening.

May 29, 2013 — Hologic Inc. announced that the U.S. Food and Drug Administration (FDA) approved the use of Hologic's new C-View 2-D imaging software. C-View 2-D images may now be used in place of the conventional 2-D exposure previously required as part of a Hologic 3-D breast tomosynthesis screening exam.

C-View images are generated from the 3-D tomosynthesis data acquired during the mammography exam, eliminating the need for additional 2-D exposures. The combination of Hologic's 3-D and C-View 2-D images results in less time under compression, for greater patient comfort and a lower radiation dose, while still providing the 2-D images required as part of Hologic's FDA-approved 3-D mammography screening exam.

“Large-scale clinical studies have shown that screening with Hologic's 3-D mammography technology allows radiologists to visualize the breast in greater detail than with 2-D mammography alone, which results in earlier detection of cancers while at the same time reducing the false positives associated with conventional 2D mammography that cause unnecessary anxiety and cost,” said Peter Soltani, Hologic senior vice president and general manager, breast health.

Hologic's 3-D mammography technology has been approved for use in countries recognizing the CE mark since 2008. It was approved for use in the United States for breast cancer screening and diagnosis in 2011. Hologic systems are now in use in 48 states and over 50 countries.

For more information: www.breasttomo.com

Related Content

Kubtec Introduces Automatic Specimen Alert to Mozart 3-D Tomosynthesis System
Technology | Breast Imaging | August 23, 2017
Kubtec announced that it has developed a unique solution to a potential problem faced by operating room (OR) staff when...
Comparison of Screening Recommendations Supports Annual Mammography
News | Mammography | August 22, 2017
When to initiate screening for breast cancer, how often to screen, and how long to screen are questions that continue...
Clinical Data Supports Use of Xoft System for Endometrial Cancer
News | Brachytherapy Systems | August 03, 2017
Researchers presented clinical data supporting use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the...
The ASPIRE Cristalle FFDM system with DBT combines Fujifilm’s state-of-the-art hexagonal close pattern (HCP) detector design, advanced image processing and image acquisition workflow
News | Women's Health | August 01, 2017
Fujifilm Medical Systems U.S.A., Inc. announced that The Mammography Center of Monterey, an ACR-accredited breast...
Sponsored Content | Videos | Breast Imaging | July 28, 2017
Nancy Cappello, Ph.D., executive director and founder of Are You Dense Inc. and Are You Dense Advocacy, explains how
Radiotherapy Prior to Surgery Reduces Secondary Tumor Risk in Early-Stage Breast Cancer Patients
News | Radiation Therapy | July 24, 2017
Moffitt Cancer Center researchers launched a first-of-its-kind study comparing the long-term benefits of radiation...
Kubtec Launches New Website For Digital Imaging and Irradiation Products
News | Digital Radiography (DR) | July 20, 2017
Kubtec announced the launch a new website focused on the applications of digital X-ray imaging and irradiation for...
Volpara Solutions to Showcase Volpara Enterprise DDP Software at AHRA 2017
News | Mammography | July 11, 2017
Volpara Solutions Inc. will showcase its new Volpara Enterprise DDP software at the Association for Medical Imaging...
Fujifilm Showcases Digital Radiography, Mammography Innovations at AHRA 2017
News | Digital Radiography (DR) | July 06, 2017
Fujifilm Medical Systems U.S.A. Inc. will present its comprehensive portfolio of digital radiography (DR) and...
Feature | Breast Density | July 05, 2017 | By Nancy M. Cappello, Ph.D.
Two decades of research on the masking risk of dense breast tissue by mammography screening is indisputable. As the...
Overlay Init